New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Sushil Pant

Dr Sushil Pant

Acutely Painful Shoulder – Assessment and Management in GP

Dr Richard Phoon

Dr Richard Phoon

Chronic Kidney Disease – Delay Progression and Prevent Dialysis

Prof Rodney Baber AM

Prof Rodney Baber AM

Understand & Explain the Risks & Side Effects of MHT

Prof Peter Richmond

Prof Peter Richmond

Invasive Pneumococcal Disease – What GPs Need to Know

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 25 July 2023